{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:06:52Z","timestamp":1787170012915,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019978","name":"Shanghai Pudong New Area Health Commission","doi-asserted-by":"publisher","award":["PWR12025-03"],"award-info":[{"award-number":["PWR12025-03"]}],"id":[{"id":"10.13039\/501100019978","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejps.2026.107599","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:00:27Z","timestamp":1782975627000},"page":"107599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["iRGD-modified peptide\u2013drug conjugate improves brain delivery and antitumor efficacy in glioblastoma"],"prefix":"10.1016","volume":"224","author":[{"given":"Danyang","family":"Yun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoli","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejps.2026.107599_bib0018","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.4155\/fmc.12.76","article-title":"Peptides and peptide conjugates: therapeutics on the upward path","volume":"4","author":"Ahrens","year":"2012","journal-title":"Future Med. Chem."},{"issue":"1 Epilepsy","key":"10.1016\/j.ejps.2026.107599_bib0017","first-page":"283","article-title":"Appendix B: AAN summary of evidence-based guideline for clinicians: management issues for women with epilepsy\u2013focus on pregnancy: obstetrical complications and change in seizure frequency","volume":"22","year":"2016","journal-title":"Continuum. (Minneap. Minn.)"},{"issue":"2","key":"10.1016\/j.ejps.2026.107599_bib0001","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13311-017-0519-x","article-title":"Glioma subclassifications and their clinical significance","volume":"14","author":"Chen","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.ejps.2026.107599_bib0005","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/pharmaceutics14051053","article-title":"Integrin-alphavbeta3 as a therapeutic target in glioblastoma: back to the future?","volume":"14","author":"Echavidre","year":"2022","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.ejps.2026.107599_bib0019","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.bmc.2018.01.012","article-title":"Peptide chemistry toolbox - transforming natural peptides into peptide therapeutics","volume":"26","author":"Erak","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"11\u201312","key":"10.1016\/j.ejps.2026.107599_bib0004","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1101\/gad.324301.119","article-title":"Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer","volume":"33","author":"Gimple","year":"2019","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejps.2026.107599_bib0023","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-1-0716-3052-5_22","article-title":"Transwell In vitro cell migration and invasion assays","volume":"2644","author":"Justus","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejps.2026.107599_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217536","article-title":"Targeting tumor microenvironment with RGD-functionalized nanoparticles for precision cancer therapy","volume":"614","author":"Lorenzoni","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2026.107599_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119666","article-title":"An iRGD-conjugated prodrug micelle with blood-brain-barrier penetrability for anti-glioma therapy","volume":"230","author":"Lu","year":"2020","journal-title":"Biomaterials"},{"issue":"24","key":"10.1016\/j.ejps.2026.107599_bib0015","first-page":"35","article-title":"IRGD-modified erythrocyte membrane biomimetic temozolomide nanodots for the treatment of glioblastoma","author":"Luo","year":"2024","journal-title":"Nanotechnology"},{"issue":"1","key":"10.1016\/j.ejps.2026.107599_bib0021","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70051","article-title":"Synthesis and investigation of peptide-drug conjugates comprising Camptothecin and a Human protein-derived cell-penetrating peptide","volume":"105","author":"Palombi","year":"2025","journal-title":"Chem. Biol. Drug Des."},{"issue":"11","key":"10.1016\/j.ejps.2026.107599_bib0022","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/pharmaceutics11110587","article-title":"IVIVC assessment of two mouse brain endothelial cell models for drug screening","volume":"11","author":"Puscas","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejps.2026.107599_bib0016","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12951-021-01180-0","article-title":"Combined integrin alpha(v)beta(3) and lactoferrin receptor targeted docetaxel liposomes enhance the brain targeting effect and anti-glioma effect","volume":"19","author":"Qi","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.ejps.2026.107599_bib0006","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1750-3639.2008.00137.x","article-title":"Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature","volume":"18","author":"Schnell","year":"2008","journal-title":"Brain Pathol"},{"issue":"6","key":"10.1016\/j.ejps.2026.107599_bib0009","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2009.10.013","article-title":"Tissue-penetrating delivery of compounds and nanoparticles into tumors","volume":"16","author":"Sugahara","year":"2009","journal-title":"Cancer Cell"},{"issue":"5981","key":"10.1016\/j.ejps.2026.107599_bib0010","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejps.2026.107599_bib0011","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/0008-5472.CAN-25-4223","article-title":"Targeting the alphavbeta5 integrin modifies the TGF-beta-rich tumor microenvironment of pancreatic cancer","author":"Suzuki","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2026.107599_bib0012","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fonc.2013.00216","article-title":"Tumor-penetrating peptides","volume":"3","author":"Teesalu","year":"2013","journal-title":"Front Oncol."},{"issue":"12","key":"10.1016\/j.ejps.2026.107599_bib0013","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bulcan.2023.08.009","article-title":"Cancer therapy with iRGD as a tumor-penetrating peptide","volume":"110","author":"Thirumalai","year":"2023","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.ejps.2026.107599_bib0007","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.stem.2020.01.007","article-title":"Playing favorites: integrin alphavbeta5 mediates preferential Zika infection of neural stem cells","volume":"26","author":"Vazquez","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.ejps.2026.107599_bib0024","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41565-021-00950-z","article-title":"Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy","volume":"16","author":"Wang","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejps.2026.107599_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-031-23705-8_1","article-title":"Malignant glioma","volume":"1405","author":"Wang","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejps.2026.107599_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116119","article-title":"Peptide-drug conjugates: a new paradigm for targeted cancer therapy","volume":"265","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107599_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-213X-8-88","article-title":"Transcriptional regulation of mouse alpha A-crystallin gene in a 148kb cryaa BAC and its derivates","volume":"8","author":"Wolf","year":"2008","journal-title":"BMC Dev. Biol."},{"issue":"5","key":"10.1016\/j.ejps.2026.107599_bib0003","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.stem.2017.10.002","article-title":"Targeting glioma stem cell-derived pericytes disrupts the blood-tumor barrier and improves chemotherapeutic efficacy","volume":"21","author":"Zhou","year":"2017","journal-title":"Cell Stem Cell"}],"updated-by":[{"DOI":"10.1016\/j.ejps.2026.107617","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000}},{"DOI":"10.1016\/j.ejps.2026.107617","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:25:35Z","timestamp":1784748335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726001739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"alternative-id":["S0928098726001739"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107599","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"iRGD-modified peptide\u2013drug conjugate improves brain delivery and antitumor efficacy in glioblastoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107599"}}